ATE234840T1 - 1-aminotriazolo 4,3-a chinazolin-5-one und/oder - thione inhibitoren von phosphodiesterasen iv - Google Patents

1-aminotriazolo 4,3-a chinazolin-5-one und/oder - thione inhibitoren von phosphodiesterasen iv

Info

Publication number
ATE234840T1
ATE234840T1 AT00967407T AT00967407T ATE234840T1 AT E234840 T1 ATE234840 T1 AT E234840T1 AT 00967407 T AT00967407 T AT 00967407T AT 00967407 T AT00967407 T AT 00967407T AT E234840 T1 ATE234840 T1 AT E234840T1
Authority
AT
Austria
Prior art keywords
aminotriazolo
phosphodiesterases
quinazolin
thione
inhibitors
Prior art date
Application number
AT00967407T
Other languages
English (en)
Inventor
Bernard Gaudilliere
Remi Lavalette
Charles Andrianjara
Francine Breuzard
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE234840T1 publication Critical patent/ATE234840T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT00967407T 1999-04-28 2000-04-28 1-aminotriazolo 4,3-a chinazolin-5-one und/oder - thione inhibitoren von phosphodiesterasen iv ATE234840T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9905398A FR2792938B1 (fr) 1999-04-28 1999-04-28 NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
PCT/FR2000/001174 WO2000066584A1 (fr) 1999-04-28 2000-04-28 1-AMINO TRIAZOLO¢4,3-a! QUINAZOLINE-5-ONES ET/OU -5-THIONES INHIBITRICES DE PHOSPHODIESTERASES IV

Publications (1)

Publication Number Publication Date
ATE234840T1 true ATE234840T1 (de) 2003-04-15

Family

ID=9544983

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00967407T ATE234840T1 (de) 1999-04-28 2000-04-28 1-aminotriazolo 4,3-a chinazolin-5-one und/oder - thione inhibitoren von phosphodiesterasen iv

Country Status (34)

Country Link
US (1) US6828315B1 (de)
EP (1) EP1177195B1 (de)
JP (1) JP2002543199A (de)
KR (1) KR20020008166A (de)
CN (1) CN1352644A (de)
AP (1) AP2001002309A0 (de)
AT (1) ATE234840T1 (de)
AU (1) AU4411500A (de)
BG (1) BG106026A (de)
BR (1) BR0010072A (de)
CA (1) CA2388658A1 (de)
DE (1) DE60001735T2 (de)
DK (1) DK1177195T3 (de)
DZ (1) DZ3154A1 (de)
EA (1) EA004373B1 (de)
EE (1) EE200100566A (de)
ES (1) ES2194779T3 (de)
FR (1) FR2792938B1 (de)
HK (1) HK1044938B (de)
HR (1) HRP20010794B1 (de)
HU (1) HUP0202656A3 (de)
IL (1) IL146178A0 (de)
IS (1) IS6114A (de)
MA (1) MA27343A1 (de)
MX (1) MXPA01010888A (de)
NO (1) NO20015235L (de)
OA (1) OA11875A (de)
PL (1) PL351951A1 (de)
PT (1) PT1177195E (de)
SK (1) SK15322001A3 (de)
TR (1) TR200103099T2 (de)
WO (1) WO2000066584A1 (de)
YU (1) YU76401A (de)
ZA (1) ZA200108847B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1199074A1 (de) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmazeutische Zusammensetzungen zur Vorbeugung oder Behandlung von mit IL-12 Überproduktion assozierten Erkrankungen
EP1188438A1 (de) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmazeutische Zusammensetzungen zur Vorbeugung oder Behandlung von mit IL-12 Überproduktion assozierten Erkrankungen
PA8539501A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
JP4510384B2 (ja) * 2001-05-23 2010-07-21 田辺三菱製薬株式会社 骨折治癒促進用組成物
EP1285922A1 (de) 2001-08-13 2003-02-26 Warner-Lambert Company 1-alkyl oder 1-cycloalkyltriazolo[4,3-a]chinazolin-5-one als phosphodiesterase Inhibitoren
FR2832711B1 (fr) * 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
AU2003277562B2 (en) * 2002-11-06 2009-03-26 Aska Pharmaceutical Co., Ltd. Pyrazolonaphthyridine derivative
KR101026819B1 (ko) * 2003-01-09 2011-04-04 아스테라스 세이야쿠 가부시키가이샤 피롤로피리다진 유도체
BRPI0510166A (pt) * 2004-04-23 2007-10-02 Celgene Corp método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2010505811A (ja) 2006-10-04 2010-02-25 ファイザー・プロダクツ・インク カルシウム受容体アンタゴニストとしてのピリド［４，３−ｄ］ピリミジン−４（３Ｈ）−オン誘導体
WO2009013286A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Organic compounds
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN103224498B (zh) * 2013-05-07 2015-10-28 陈定奔 两种唑并喹唑啉酮稠杂环的新合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865824A (en) * 1972-03-07 1975-02-11 Icn Pharmaceuticals 2-Aryl-7-substituted pyrazolo {8 1,5{i a{b {9 1,3,5-triazines
US3850932A (en) * 1973-06-28 1974-11-26 Sandoz Ag 5-(2-carboxy and 2-carboalkoxy-phenylamino)-1,2,4-triazolo-quinazolines
IL66835A (en) * 1981-09-24 1988-05-31 Roussel Uclaf 1,4-disubstituted(1,2,4)triazolo(4,3-alpha)quinazolin-5(4h)-one derivatives and their salts,their preparation and pharmaceutical compositions containing them
JPS6028979A (ja) * 1983-07-14 1985-02-14 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン類化合物
DE69525978T2 (de) * 1995-06-06 2002-12-19 Pfizer Trizyclische 5,6-dihydro-9h-pyrazolo(3,4-c)-1,2,4-triazolo(4,3-alpha)pyridine
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.

Also Published As

Publication number Publication date
BG106026A (bg) 2002-05-31
CN1352644A (zh) 2002-06-05
OA11875A (en) 2006-03-29
HUP0202656A3 (en) 2004-12-28
ES2194779T3 (es) 2003-12-01
HRP20010794A2 (en) 2003-04-30
HK1044938A1 (en) 2002-11-08
EA004373B1 (ru) 2004-04-29
EP1177195B1 (de) 2003-03-19
WO2000066584B1 (fr) 2001-02-15
EE200100566A (et) 2003-02-17
EP1177195A1 (de) 2002-02-06
WO2000066584A1 (fr) 2000-11-09
HUP0202656A2 (hu) 2002-12-28
DE60001735D1 (de) 2003-04-24
IS6114A (is) 2001-10-19
NO20015235D0 (no) 2001-10-26
PT1177195E (pt) 2003-07-31
ZA200108847B (en) 2002-11-27
FR2792938A1 (fr) 2000-11-03
KR20020008166A (ko) 2002-01-29
YU76401A (sh) 2004-07-15
CA2388658A1 (en) 2000-11-09
JP2002543199A (ja) 2002-12-17
EA200100994A1 (ru) 2002-06-27
HRP20010794B1 (en) 2004-06-30
DE60001735T2 (de) 2004-02-05
BR0010072A (pt) 2002-02-05
HK1044938B (zh) 2003-12-24
MXPA01010888A (es) 2003-06-24
FR2792938B1 (fr) 2001-07-06
IL146178A0 (en) 2002-07-25
DK1177195T3 (da) 2003-07-14
AU4411500A (en) 2000-11-17
NO20015235L (no) 2001-12-21
DZ3154A1 (fr) 2000-11-09
SK15322001A3 (sk) 2002-11-06
AP2001002309A0 (en) 2001-12-31
PL351951A1 (en) 2003-07-14
MA27343A1 (fr) 2005-06-01
US6828315B1 (en) 2004-12-07
TR200103099T2 (tr) 2002-12-23

Similar Documents

Publication Publication Date Title
ATE234840T1 (de) 1-aminotriazolo 4,3-a chinazolin-5-one und/oder - thione inhibitoren von phosphodiesterasen iv
ATE306487T1 (de) Purinhemmer von cyclinabhängiger kinase 2 und ikb-alpha
ATE277895T1 (de) 4-brom or 4-iod-phenylamino- benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
ATE309224T1 (de) Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren
ATE302193T1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
CY2006007I2 (el) Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
EE200100659A (et) Diaminotiasoolid ja nende kasutamine proteiinikinaaside pärssimiseks
ID30393A (id) Senyawa tienopirimidina, pembuatan dan penggunaannya
ATE332294T1 (de) Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung
DE60009888D1 (de) Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen
DE69826693D1 (de) Amidinoderivate und ihre verwendung als thrombininhibitoren
FR2776660B1 (fr) Diazepino-indoles de phosphodiesterases iv
DE50008549D1 (de) Triazolotriazinone und ihre verwendung
ATE253059T1 (de) Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2- one und ihre verwendung als lipase-hemmer
PT1152756E (pt) Derivados de anticonvulsivo uteis no tratamento do autismo
HU9802886D0 (en) Substituted heterocyclic benzocycloalkenes and their use as analgetic active ingredients
AR027832A1 (es) Metodos de tratamiento y metodos de rastreo de farmacos
DE60020583D1 (de) Synchronisierung von pcm und pseudozufallstaktgebern
ATE346840T1 (de) Aminoalkylphenol-derivate zur behandlung von depression und gedächtnis-funktionsstörung
EE04494B1 (et) 1-oksa-, asa- ja tianaftaleen-2-oon biseetrid fosfolambaani inhibiitoritena
NO20014729D0 (no) Derivater av pyrimido[6,1-A]isokinolin-4-on og anvendelse derav
PT1325010E (pt) 3, 4-di-hidropirimido [1,2-a] pirimidinas e 3, 4-di-hidropirazino [1,2-a] pirimidinas substituidas
NO20005856D0 (no) Anvendelse av 1,1-diokso-perhydro-1,2,4-tiadiaziner
ES1046207Y (es) Corrector de gesticulacion antiarrugas y antiojeras.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1177195

Country of ref document: EP

REN Ceased due to non-payment of the annual fee